Skip to main content

Day: March 25, 2026

Picard Medical Reports Full Year 2025 Financial Results

Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the year ended December 31, 2025. The year reflected a transformational period for the Company highlighted by revenue growth, improved operating performance, and a strengthened balance sheet following the successful completion of the Company public listing and related capital raises. Key Financial HighlightsRevenue of $4.9 million, an increase of 12.5 percent compared to 2024 Product revenue of $4.7 million representing 96 percent of total revenue Gross margin was (4.1 percent)...

Continue reading

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for...

Continue reading

Bessor Announces Termination of Jagrite Graphite Project

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, BC, March 25, 2026 (GLOBE NEWSWIRE) — Bessor Minerals Inc. (TSXV:BST) (“Bessor” or the “Corporation”) would like to announce that further to its press release dated September 10, 2025, it has terminated the asset purchase agreement to acquire the Jagrite Graphite Project located near the Bella Coola area in British Columbia. ABOUT BESSOR MINERALS INC. Bessor’s focus is on exploration and development its Golden Eagle property in the Yukon and the Redhill volcanogenic massive sulphide deposit in British Columbia. In addition, Bessor has a 1% NSR on certain claims in the Blackwater Mine operated by Artemis Gold Inc. BESSOR MINERALS INC. Jason RileyPresident, CEO & Director For further information, contact: Investor...

Continue reading

NOTICE TO THE ANNUAL GENERAL MEETING OF TULIKIVI CORPORATION 2026

TULIKIVI CORPORATION   STOCK EXCHANGE RELEASE   25 MARCH 2026 AT 1:00 P.M. EET Notice is given to the shareholders of Tulikivi Corporation to the Annual General Meeting to be held on Thursday 22 April 2026 starting at 12:00 p.m. at the premises of Borenius Attorneys Ltd, Eteläesplanadi 2, 00130 Helsinki. The reception of persons who have registered for the meeting will commence at 11:30 a.m. A. Matters on the agenda of the general meeting The following matters will be considered at the Annual General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Presentation of the annual accounts, which include the consolidated...

Continue reading

CMG Announces the Acquisition of Rose Subsurface Assessment

Expands CMG’s capabilities to probabilistic subsurface risk and resource assessment CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) (TSX: CMG) today announces that it has acquired Rose Subsurface Assessment (“Rose”), a globally recognized provider of probabilistic subsurface risk analysis and resource assessment software, training, consulting, and operator consortium services for the global exploration and production industry. Key Acquisition HighlightsPurchase consideration USD $9.8 million, consisting of USD $8.8 million paid in cash at closing, plus an amount equivalent to Rose’s cash on hand immediately prior to closing, with the remainder subject to a customary holdback, and a potential earn‑out of up to USD $2.5 million tied to performance milestones Trailing twelve-month...

Continue reading

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash and represents an approximate premium of 31% to the 60-day and 42% to the 90-day volume-weighted average stock...

Continue reading

Akamai Launches Brand Guardian to Help Enterprises Combat Automated Fraud

AI-powered solution identifies and disrupts brand impersonation across the web, social media, email, app stores, and the dark web to protect customer trust and revenue CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) — Akamai (NASDAQ: AKAM) today introduced Akamai Brand Guardian. This evolution of Akamai Brand Protector adds proactive, AI-powered capabilities that can help global enterprises identify and manage brand impersonation at scale. Scammers are exploiting the widespread availability of generative AI to deploy sophisticated fake websites and digital identities in seconds, making it nearly impossible for businesses to keep pace using manual discovery methods. For companies in sectors like financial services, retail, and healthcare, these fraudulent sites threaten digital integrity, which often leads to lost revenue and damaged...

Continue reading

Amaze Highlights First Quarter 2026 Achievements and Upcoming Priorities in Letter to Shareholders

NEWPORT BEACH, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today issued a letter to its shareholders highlighting achievements in Q1 and priorities for the remainder of 2026. Dear Shareholders, As we move through the first quarter of 2026, I want to take a moment to update you on our progress and how we are thinking about the next phase of Amaze. In our year-end letter, we spoke about 2025 as a transformative year—one where we stabilized the business, reduced our cost structure, strengthened the balance sheet, and positioned ourselves for growth. That work is now largely behind us. Our focus has shifted from fixing the foundation to scaling the opportunity. From Foundation to Flywheel Amaze has always been built around...

Continue reading

ADMA Biologics Addresses Misleading Short-Seller Report

RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a report issued on March 24, 2026 by Culper Research (the “Short Report”), a firm that has published similarly negative “research reports” regarding public companies after taking short positions in the stock. The Short Report discloses that Culper Research holds a short position in ADMA. ADMA, and its Board of Directors takes seriously its obligations to fairly and accurately report its operating and financial results and make all public disclosures in accordance with the rules and regulations of the U.S. Securities and Exchange Commission and in accordance...

Continue reading

NOV Announces Expansion of Subsea Flexible Pipe Manufacturing Capacity to Support Growing Demand

NOV to roughly double the capacity of its manufacturing facility in Brazil over the next three years to support anticipated demand $200 million capital expansion positions NOV to capture expected growth in offshore development activity and advance solutions for high-CO₂ applications Sustained high utilization and strong backlog across existing facilities support the need for additional capacityHOUSTON, March 25, 2026 (GLOBE NEWSWIRE) — NOV Inc. (NYSE: NOV) today announced plans to roughly double the capacity of its subsea flexible pipe manufacturing facility in Açu, Brazil, through a $200 million investment over the next three years. “We are expanding our subsea flexible pipe manufacturing facility in Açu, Brazil to support what we see as sustained, long-term demand,” said Jose Bayardo, Chairman, President and Chief Executive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.